首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | INHBC |
| Uniprot No | P55103 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 237-352aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGIDCQGGSRMCCRQEFFVDFREIGWHDWI IQPEGYAMNFCIGQCPLHIAGMPGIAASFHTAVLNLLKANTAAGTTGGGS CCVPTARRPLSLLYYDRDSNIVKTDIPDMVVEACGCS |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于INHBC重组蛋白的假设性参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**：*Recombinant INHBC promotes TGF-β signaling in cancer progression*
**作者**：Smith J. et al. (2019)
**摘要**：研究通过哺乳动物细胞表达系统获得重组INHBC蛋白，发现其可激活Smad信号通路，促进癌细胞侵袭和转移，提示INHBC在肿瘤微环境中的作用。
2. **文献名称**：*Expression and purification of bioactive INHBC in E. coli*
**作者**：Zhang L. et al. (2020)
**摘要**：报道了利用大肠杆菌表达系统高效生产重组INHBC蛋白的方法，并通过体外实验验证其与激活素受体结合的能力，为后续功能研究提供工具。
3. **文献名称**：*INHBC recombinant protein inhibits muscle differentiation via BMP signaling*
**作者**：Lee S. et al. (2021)
**摘要**：研究发现重组INHBC蛋白通过结合ActRIIB受体抑制成肌细胞分化，揭示其在骨骼肌再生中的调控机制。
4. **文献名称**：*Structural analysis of INHBC reveals key domains for receptor interaction*
**作者**：Brown K. et al. (2018)
**摘要**：通过X射线晶体学解析重组INHBC蛋白的三维结构，鉴定其与Ⅱ型受体结合的特定区域，为靶向药物设计提供依据。
---
**注意**：以上为模拟示例，实际文献需通过**PubMed**、**Google Scholar**或**Web of Science**等平台检索(关键词：INHBC recombinant protein, inhibin beta C expression)。建议结合具体研究方向筛选近年高被引论文。
**Background of INHBC Recombinant Protein**
INHBC (Inhibin Beta C) is a subunit of inhibins and activins, which belong to the transforming growth factor-beta (TGF-β) superfamily. These proteins play critical roles in regulating cellular processes such as proliferation, differentiation, apoptosis, and immune response. Inhibins and activins are dimeric proteins: inhibins consist of an α-subunit (INHA) and a β-subunit (INHBA, INHBB, or INHBC), while activins are homo- or heterodimers of β-subunits. Specifically, INHBC contributes to forming activin AC (βA-βC) or activin BC (βB-βC) complexes, which bind to activin receptors and modulate SMAD-dependent signaling pathways.
INHBC is less characterized compared to other β-subunits (e.g., INHBA or INHBB) but has been implicated in reproductive biology, cancer progression, and tissue homeostasis. Its expression is detected in various tissues, including the liver, placenta, and certain tumors. Dysregulation of INHBC is associated with pathologies such as fibrosis, polycystic ovary syndrome (PCOS), and malignancies, where it may influence TGF-β signaling crosstalk or act as a biomarker.
Recombinant INHBC protein is produced using engineered mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and bioactivity. It is purified via affinity chromatography and validated through techniques like SDS-PAGE, Western blot, and functional assays (e.g., cell-based luciferase reporter tests). Researchers utilize this protein to study INHBC-specific signaling mechanisms, receptor interactions, and its role in disease models. Additionally, it serves as a tool for developing therapeutic agents targeting activin-related pathways in conditions like cancer cachexia, osteoporosis, or metabolic disorders.
Ongoing studies aim to elucidate INHBC's distinct functions and therapeutic potential, bridging gaps in understanding TGF-β family complexity.
×
